As the leading Duchenne muscular dystrophy charity in the UK, we want to find effective treatments for DMD and end its devastating impact. We connect the best researchers with industry, the NHS and families to advance and accelerate every stage of drug development.
We need to go further than anyone has before to find effective treatments. This means setting our ambitions high and overcoming every barrier in our way.
We’re going to do it faster, because this generation of people living with DMD can’t wait.
The only way we can achieve this is together. We create a network of mutual support for families. We collaborate with scientists and the pharmaceutical industry, bringing them together to share knowledge. And we work with health services so that patients get the care they need.
Our Parent Information Days are back!
Information days are free to attend for parents or caregivers in the UK who have a child diagnosed with Duchenne muscular dystrophy. Our next event will take place in Manchester on 2 October 2021.
Duchenne muscular dystrophy (DMD) is a life-limiting genetic disease which causes progressive muscle weakening.
About DMD
Join our fight to fund life-changing treatments for DMD by fundraising, donating, or joining an event.
Get involved
The DMD Hub is a network of trial sites carrying out clinical trials for Duchenne muscular dystrophy.
Visit the DMD Hub site
The Joint Committee on Vaccination and Immunisation (JCVI) is now advising that children at increased risk of serious COVID-19 disease should be offered the Pfizer-BioNTech vaccine.
Read More
Calling all parents of children/young people with Duchenne muscular dystrophy and adults with DMD - join our psycho-social care focus group and help inform the work of the DMD Care UK project to improve psycho-social care.
Read More
Selecting which DMD treatments to advance to human testing is a critical decision. In 2020, Duchenne UK joined with US-based charity Charley’s Fund to improve the data collected in preclinical research.
Read More
Dr Emily Whitehouse is the latest consultant to join the fight against DMD at the Royal Manchester Children’s Hospital, which is part of the DMD Hub network of clinical trial sites.
Read More
Duchenne UK is delighted to announce that Vamorolone, a drug to treat Duchenne muscular dystrophy (DMD), has shown positive results in a Phase 2 Study.
Read More
Duchenne UK has announced a further four years of funding for the DMD Hub Manager role to continue to increase DMD clinical trial capacity in the UK.
Read More
Duchenne UK have funded a study that aims to improve our knowledge of treating heart muscle disease in patients with Duchenne muscular dystrophy (DMD).
Read More
Pfizer have announced the enrolment of their first participant in a Duchenne muscular dystrophy (DMD) gene therapy trial in the UK.
Read More
Pharmaceutical companies Santhera Pharmaceuticals and ReveraGen BioPharma have announced new data from their clinical study of a potential treatment for Duchenne muscular dystrophy (DMD) that could replace the current standard of care, corticosteroids.
Read More
Sign up for the latest news on DMD research, upcoming events and ways to get involved.
